Satellos Bioscience Fast Track Win Fuels DMD Hopes
Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market
Abivax SA (ABVX:NASDAQ) UC Data Fuels Biotech Opportunity
Clinical-Stage Biotech Discloses Colitis Retreatment Results, Gets Mixed Ratings
DarioHealth (DRIO) Expands Reach via Beluga Health Deal
Digital Health Pioneer Targets Massive Breakthrough Chronic Care Market
Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1
A New Obesity Drug Just Reached Human Trials. Here's What Comes Next
Viking Therapeutics Inc. (VKTX:NASDAQ) initiated a Phase 1 clinical trial of its investigational weight-loss candidate VK3019, following FDA clearance of its IND application.uniQure Epilepsy Gene Therapy Data Draws Investor Focus
uniQure reports early AMT-260 results for refractory MTLE. See the trial data, pipeline catalysts, analyst price target, and what retail investors should watch next.Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment, Gets Buy Rating
uniQure N.V. (QURE:NASDAQ) announced initial six-month data for AMT-260 treating refractory epilepsy, with three of six patients showing 79-100% seizure reduction.San Diego Biopharma Begins First-in-Human Dosing of Obesity Drug as Phase 3 Catalysts Approach
Research Report
A San Diego clinical-stage biopharma dosed its first patient in a Phase 1 obesity study while advancing late-stage weight-loss programs toward key 20262027 readouts. 
Streetwise Key Charts
